Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
Visceral metastasis (VM) and a higher number of bone metastasis generally define high
volume/risk in patients with metastatic castration-sensitive prostate cancer (mCSPC) …
volume/risk in patients with metastatic castration-sensitive prostate cancer (mCSPC) …
Pattern of clinical progression until metastatic castration-resistant prostate cancer: An epidemiological study from the european prostate cancer registry
C Verry, S Vincendeau, M Massetti, M Blachier… - Targeted Oncology, 2022 - Springer
Abstract Background Prostate cancer (PCa) is the most frequently diagnosed cancer in men
in Europe. The impact of PCa natural history and therapeutic management on the outcomes …
in Europe. The impact of PCa natural history and therapeutic management on the outcomes …
Recent advances in anticancer peptoids
J Zhu, S Chen, Z Liu, J Guo, S Cao, S Long - Bioorganic Chemistry, 2023 - Elsevier
Since most tumors become resistant to drugs in a gradual and irreversible manner, making
treatment less effective over time, anticancer drugs require continuous development …
treatment less effective over time, anticancer drugs require continuous development …
Administration of radium‐223 and the prognosis in Japanese bone metastatic castration‐resistant prostate cancer patients: A large database study
T Kawahara, Y Miyoshi, S Ninomiya… - … Journal of Urology, 2022 - Wiley Online Library
Background The ALSYMPCA trial revealed radium‐223 (Ra‐223) to be a life‐prolonging
agent for bone metastatic castration‐resistant prostate cancer (CRPC). However, only 2.8 …
agent for bone metastatic castration‐resistant prostate cancer (CRPC). However, only 2.8 …
[HTML][HTML] Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
S Chikamatsu, M Shiota, S Yamada, L Blas… - Prostate …, 2022 - Elsevier
Abstract Background The CHAARTED and LATITUDE trials demonstrated a survival benefit
of docetaxel and abiraterone for hormone-sensitive prostate cancer. In this study, we …
of docetaxel and abiraterone for hormone-sensitive prostate cancer. In this study, we …
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a …
T Yanagisawa, T Kimura, K Hata, S Narita… - World Journal of …, 2023 - Springer
Purpose The aim of this study was to investigate the oncologic efficacy of combining
docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen …
docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen …
Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
T Büttner, N Klümper, R Weiten, P Lossin, S Latz… - The …, 2024 - Wiley Online Library
Background The prognosis of metastatic castration‐resistant prostate cancer (mCRPC) is
influenced by numerous individual factors. Despite various proposed prognostic models, the …
influenced by numerous individual factors. Despite various proposed prognostic models, the …
The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer
T Oka, K Hatano, Y Okuda, A Yamamoto… - International Journal of …, 2023 - Springer
Background Enzalutamide is effective against castration-resistant prostate cancer (CRPC).
However, it is unclear which patients would benefit more from enzalutamide treatment. Here …
However, it is unclear which patients would benefit more from enzalutamide treatment. Here …
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone …
S Tsuzuki, S Kawano, W Fukuokaya… - Japanese Journal of …, 2021 - academic.oup.com
Background Randomized trials showed the survival benefits of the combined use of
androgen receptor axis-targeted agents with androgen deprivation therapy in metastatic …
androgen receptor axis-targeted agents with androgen deprivation therapy in metastatic …
The effect of frailty on the quality of life and lower urinary symptoms following robot-assisted radical prostatectomy: A longitudinal analysis (FRARP-QL Study)
K Togashi, S Hatakeyama, Y Kojima, M Momota… - … Oncology: Seminars and …, 2021 - Elsevier
Objectives We aimed to evaluate the effect of frailty on health-related quality-of-life (HRQOL)
and lower urinary symptoms (LUTS) following robot-assisted radical prostatectomy (RARP) …
and lower urinary symptoms (LUTS) following robot-assisted radical prostatectomy (RARP) …